4.7 Review

Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events

Journal

ARCHIVES OF TOXICOLOGY
Volume 96, Issue 1, Pages 11-78

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00204-021-03171-4

Keywords

Chemobrain; Chemofog; Neurotoxicity; Cognitive impairment; Chemotherapy

Categories

Funding

  1. FCT-Fundacao para a Ciencia e a Tecnologia, I.P. [UIDP/04378/2020, UIDB/04378/2020, LA/P/0140/2020]
  2. Associate Laboratory Institute for Health and Bioeconomy-i4HB [EXPL/MED-FAR/0203/2021]
  3. Innovative Medicines Initiative 2 Joint Undertaking [821528]
  4. European Union
  5. European Federation of Pharmaceutical Industries and Associations (EFPIA)
  6. FCT [SFRH/BD/129359/2017]
  7. UCIBIO [UI/BD/151318/2021]
  8. FCT under the Norma Transitoria [DL57/2016/CP1334/CT0006]
  9. Fundação para a Ciência e a Tecnologia [EXPL/MED-FAR/0203/2021, SFRH/BD/129359/2017] Funding Source: FCT

Ask authors/readers for more resources

Chemotherapy-induced cognitive dysfunction has a significant impact on cancer patients, affecting domains such as verbal memory and psychomotor function. Studies suggest that chemotherapy alters brain metabolism, white and grey matter, while the underlying neurotoxic mechanism of cognitive deficits is still not fully elucidated.
Cognitive dysfunction has been one of the most reported and studied adverse effects of cancer treatment, but, for many years, it was overlooked by the medical community. Nevertheless, the medical and scientific communities have now recognized that the cognitive deficits caused by chemotherapy have a strong impact on the morbidity of cancer treated patients. In fact, chemotherapy-induced cognitive dysfunction or 'chemobrain' (also named also chemofog) is at present a well-recognized effect of chemotherapy that could affect up to 78% of treated patients. Nonetheless, its underlying neurotoxic mechanism is still not fully elucidated. Therefore, this work aimed to provide a comprehensive review using PubMed as a database to assess the studies published on the field and, therefore, highlight the clinical manifestations of chemobrain and the putative neurotoxicity mechanisms. In the last two decades, a great number of papers was published on the topic, mainly with clinical observations. Chemotherapy-treated patients showed that the cognitive domains most often impaired were verbal memory, psychomotor function, visual memory, visuospatial and verbal learning, memory function and attention. Chemotherapy alters the brain's metabolism, white and grey matter and functional connectivity of brain areas. Several mechanisms have been proposed to cause chemobrain but increase of proinflammatory cytokines with oxidative stress seem more relevant, not excluding the action on neurotransmission and cellular death or impaired hippocampal neurogenesis. The interplay between these mechanisms and susceptible factors makes the clinical management of chemobrain even more difficult. New studies, mainly referring to the underlying mechanisms of chemobrain and protective measures, are important in the future, as it is expected that chemobrain will have more clinical impact in the coming years, since the number of cancer survivors is steadily increasing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available